Stock PV3B EYEPOINT PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Market Closed - Deutsche Boerse AG
Other stock markets
 14:29:01 28/06/2024 BST 		5-day change 1st Jan Change
8.096 EUR +8.12% Intraday chart for EyePoint Pharmaceuticals, Inc. +8.18% -61.81%
06-26 EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024 CI
06-26 Transcript : EyePoint Pharmaceuticals, Inc. - Special Call

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024
CI
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M
MT
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Gain Pre-Bell Monday
MT
EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint
MT
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
DJ
EyePoint Pharmaceuticals, Inc. Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy
CI
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell
MT
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M
MT
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
CI
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals
MT
EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema
CI
EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints
CI
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q3 Revenue $15.2M, vs. Street Est of $7.4M
MT
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023
CI
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Reports Q2 Revenue $9.1M, vs. Street Est of $42.1M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EYPT Stock
  4. PV3B Stock
  5. News EyePoint Pharmaceuticals, Inc.
  6. Highlights